Lantheus Holdings, Inc.
Rank #143HypergrowthLNTH · Nasdaq · Healthcare
Lantheus Holdings, Inc. (LNTH) — Rank #143 by gross profitability (GP/assets 0.39) · ROE 17.8% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001521036 · all metrics point-in-time as of the filing date.
About
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Show moreShow less
The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC.
The company was founded in 1956 and is based in Bedford, Massachusetts.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- lantheus.com
Financials
Strengthening
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginstable
- Gross profitabilitydeteriorating
- Net cashimproving
- Operating marginimproving
- Return on equityimproving
- Share count (dilution)improving
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2019-12-31filed 2020-02-25 | 2018-12-31filed 2019-02-20 | 2017-12-31filed 2018-02-26 | 2016-12-31filed 2017-02-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 347.3 | 343.4 | 331.4 | 301.9 |
| Revenue growth (YoY) | 4.8% | 3.6% | 9.8% | 2.9% |
| Gross profit | 174.8 | 174.9 | 162.1 | 137.8 |
| Gross margin | 50.3% | 50.9% | 48.9% | 45.6% |
| Net income | 31.7 | 40.5 | 123.4 | 26.8 |
| Net margin | 9.1% | 11.8% | 37.2% | 8.9% |
| EPS (diluted) | $0.79 | $1.03 | $3.17 | $0.82 |
| EPS growth (YoY) | -23.3% | -67.5% | 286.6% | — |
| Cash flow | ||||
| Operating cash flow | 80.4 | 61.2 | 54.8 | 49.6 |
| Capital expenditures | 22.1 | 20.1 | 17.5 | 7.4 |
| Free cash flow | 58.3 | 41.1 | 37.2 | 42.2 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?